CAR T-cell therapy results in a high incidence of cytokine release syndrome, but it is manageable in most cases. The review, encompassing 19 studies, reveals a high incidence of CRS in patients with ...

Autoimmune diseases stem from a complicated interplay of immune dysregulation, characterized by chronic inflammation and the loss of self-tolerance. Cytokines are central to these processes. These ...

Obe-cel is the first FDA-approved CAR T-cell therapy for B-ALL without a REMS requirement, based on the FELIX trial's positive outcomes. The FELIX trial reported a 63% complete remission rate, with 42 ...

People often get immunotherapy as a treatment for cancer. These immunotherapy treatments can be effective, but they may cause your immune system to have an unnatural response. Your body, as a result ...

Dendritic cells (DCs) are exceptionally potent antigen-presenting cells (APCs) in the human body and are considered the “sentinels” of the immune system. They are essential in establishing, ...

Please provide your email address to receive an email when new articles are posted on . Last November, results from the MITIGATE trial made headlines at ACR Convergence 2024 with positive phase 3 ...

Memorial Sloan Kettering Cancer Center investigators report that T cell interferon-γ (IFNγ) orchestrates a dendritic-cell–natural-killer-cell circuit that suppresses leptomeningeal metastases in mouse ...

In patients with relapsed or refractory systemic lupus erythematosus, allogeneic CAR-NK cell therapy may offer a safe ...